> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 drug added to SGLT2 inhibitor in CKD tracked with fewer kidney and heart events
- URL: https://www.coios.me/glp-1-drug-added-to-sglt2-inhibitor-in-ckd-tracked-with/
- Published: 2026-09-29T12:50:10.000Z
- Updated: 2026-09-29T20:59:11.000Z
- Description: In a propensity-matched TriNetX cohort of 32,448 adults with chronic kidney disease, adding a GLP-1 receptor agonist to SGLT2 inhibitor therapy was associated with lower major adverse kidney events (HR 0.70), MACE (HR 0.83) and all-cause mortality (HR 0.55) over a median 12 months.
- Author: Daniel Ryan
- Tags: Healthcare today, Heart and stroke, Obesity, diabetes and GLP-1, World, #peer-reviewed, #new, #item, #source-2026-09

A retrospective cohort from the TriNetX global network compared adults with chronic kidney disease on an SGLT2 inhibitor alone with those who subsequently added a GLP-1 receptor agonist, matching 16,224 patients per group. Over a median of 12 months, combination therapy was associated with hazard ratios of 0.70 for major adverse kidney events, 0.83 for major adverse cardiovascular events and 0.55 for all-cause mortality. Gastrointestinal symptoms, genital infections and retinopathy progression were more common, and volume depletion and acute kidney injury less so.

*Why it is interesting: A real-world comparison of combined incretin and SGLT2 inhibitor therapy, where the size of the mortality association in an observational cohort leaves confounding by indication open.*

Source

[Diabetes, Obesity and Metabolism, 27 September 2026](https://doi.org/10.1111/dom.71375?ref=coios.me)

DOI

10.1111/dom.71375

Type

Peer-reviewed article

Design

Retrospective propensity-matched cohort, TriNetX global network, 32,448 adults with CKD, 2020-2023, median 12 months follow-up

Verdict

New finding

Driver

[Heart and stroke](https://www.coios.me/d-cardiovascular/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)